The divestiture strengthens MacroGenics' balance sheet and focuses resources on R&D. Monitor pipeline data readouts and potential partnerships, especially for lorigerlimab and TZIELD, as key catalysts.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 2 $4.71entry
- T+1 · 4mo ago −2.97%α −3.85% · $4.57
- T+5 · 4mo ago −2.97%α −3.90% · $4.57
- T+20 · 4mo ago −19.75%α −19.33% · $3.78
- T+60 · 7w ago −19.32%α −22.33% · $3.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitioning to an asset-light R&D model and securing cash to fund its pipeline. The deal includes a supply agreement for continued production support.
Key Financial Metrics
Key Facts
- Sale of GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million
- Approximately 140 employees transferred to Bora
- Supply agreement signed for process development and production for MacroGenics' pipeline
Financial Impact
Proceeds of $122.5 million before expenses represent about 42% of market cap, providing significant cash runway.
Risk Factors
- Dependence on Bora for manufacturing could create supply chain risk
- Execution risk in transitioning to outsourced manufacturing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321364 |
Track record
21 reports on MGNX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers